Synthetic nucleic acid co-transcriptional networks as diagnostic and therapeutic tools

Introduction

The heterogeneity of tumors often makes their diagnosis and treatment a very hard task. A single tumor can have many different diagnostically relevant molecular markers which can also be used to monitor the efficacy of treatment. Innovative, simple, cost-effective, and quantitative analytical tools for diagnostic and therapeutic applications are urgently needed to ensure rapid and appropriate patient care.

Project Overview

What

The CO-TRANS-NET project addresses this need by developing synthetic nucleic acid units that can respond to a wide range of tumor biomarkers and can provide innovative tools for biosensing and therapeutics through cell-free in-vitro transcription.

How

The ground-breaking idea of CO-TRANS-NET is to harness the high programmability of synthetic nucleic acids together with the high sensitivity and versatility of cell-free systems to develop co-transcriptional networks that, in one pot, through nature-inspired recognition mechanisms, can respond to a variety of targets including:

1. Proteins
2. Small molecules
3. Antibodies

These networks can trigger in-vitro transcription of functional RNA. The transcribed RNA can provide a measurable signal or produce a therapeutic drug.

Objectives

CO-TRANS-NET aims to develop single theranostic nanodevices in which cancer diagnosis and therapy can be simultaneously achieved. This goes beyond the state of the art and represents a breakthrough in the field of diagnostics, biosensing, synthetic biology, and nucleic acid-based therapeutics.